Industry Overview - The MedTech sector has emerged as a resilient investment option amid macroeconomic challenges, characterized by innovation and a rising demand for personalized healthcare solutions [6][8] - The global MedTech industry market is projected to grow to $694.70 billion by 2025, with an estimated year-over-year increase of approximately 4% [8] Market Dynamics - The medical device industry has historically been a reliable refuge during turbulent market periods, with investors currently prioritizing long-term stability over short-term gains [4] - Innovations in artificial intelligence, robotics, and minimally invasive techniques are expected to revolutionize healthcare services, increasing the demand for advanced medical equipment and diagnostic instruments [8] Company Highlights - **Fresenius Medical Care AG (FMS)**: A leading provider of products and services for dialysis patients, recently launched the NxStage Versi HD home dialysis machine, with over 14,000 U.S. patients using its system [10][11] - FMS has a Zacks Rank of 1 and a Value Score of A, with a P/E ratio of 11.36X, below the industry average of 23.48X, and is expected to see a 27.1% growth in earnings by 2025 [12] - **Phibro Animal Health (PAHC)**: A global diversified animal health company that recently acquired Zoetis Inc.'s product portfolio, enhancing its profitability and EBITDA margin [14][15] - PAHC holds a Zacks Rank of 1 and a Value Score of B, with a P/E of 9.88X, below the industry average of 15.56X, and is projected to achieve 63% growth in earnings by 2025 [16] - **Cencora, Inc. (COR)**: A major pharmaceutical services company that launched Accelerate Pharmacy Solutions and is expanding its leadership in specialty products through strategic acquisitions [17][18] - COR has a Zacks Rank of 2 and a Value Score of B, with a P/S ratio of 0.18X, significantly lower than the industry average of 1.29X, and is expected to see an 11.6% growth in earnings by 2025 [19]

Market Overview - Wall Street experienced significant declines following President Trump's announcement of sweeping tariffs, with the S&P 500 dropping 4.8%, marking its worst day since June 2020 [4]. - The Dow Jones Industrial Average fell by 1,679.39 points, or 4%, while the Nasdaq Composite decreased by 6%, both also recording their worst days since June and March 2020 respectively [4]. - Over 400 constituents of the S&P 500 ended in negative territory, reflecting a broader market rout, with the S&P 500 now down 12% from its all-time high achieved in February [5]. Tariff Impact - Trump imposed a 10% baseline tariff on all countries effective April 5, along with additional "reciprocal" tariffs on countries deemed major offenders, including Japan, Israel, and EU nations starting April 9 [6]. - The tariffs are expected to impact multinational companies significantly due to their production units located outside the United States [5]. Economic Sentiment - Investor confidence was shaken by the unexpected harshness of the tariffs, leading to fears of a potential recession, despite previous assurances from Trump regarding flexibility in tariff implementation [7]. - The ongoing volatility in the markets since February, coupled with rising inflation, may delay the Federal Reserve's next interest rate cut [8]. Defensive Investment Opportunities - In light of the current market conditions, investing in defensive stocks, particularly in the healthcare sector, is recommended. Notable stocks include Gilead Sciences, Inc. (GILD), Cencora, Inc. (COR), Fresenius Medical Care AG (FMS), and LeMaitre Vascular, Inc. (LMAT), all of which have favorable Zacks Ranks [2][3]. Company Profiles - **Gilead Sciences, Inc. (GILD)**: A leader in HIV treatment with an expected earnings growth rate of 70.4% for the current year and a Zacks Rank of 2. GILD has a beta of 0.32 and a dividend yield of 2.82% [9][10]. - **Cencora, Inc. (COR)**: A major pharmaceutical services company with an expected earnings growth rate of 11.6% and a Zacks Rank of 2. COR has a beta of 0.55 and a dividend yield of 0.79% [11][12]. - **Fresenius Medical Care AG (FMS)**: A leading provider of dialysis services with an expected earnings growth rate of 27.1% and a Zacks Rank of 1. FMS has a beta of 0.93 and a dividend yield of 1.79% [13][14]. - **LeMaitre Vascular, Inc. (LMAT)**: A provider of vascular treatment devices with an expected earnings growth rate of 16.6% and a Zacks Rank of 2. LMAT has a beta of 0.89 and a dividend yield of 0.92% [15][16].

Group 1 - Cencora (COR) has gained approximately 24.4% year-to-date, outperforming the average gain of 2% in the Medical sector [4] - Cencora holds a Zacks Rank of 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] - The Zacks Consensus Estimate for Cencora's full-year earnings has increased by 0.1% over the past quarter, reflecting improving analyst sentiment [3] Group 2 - Cencora is part of the Medical Services industry, which consists of 58 stocks and currently ranks 77 in the Zacks Industry Rank [5] - The Medical Services industry has an average gain of 3.9% year-to-date, indicating that Cencora is performing better than its industry peers [5] - Intensity Therapeutics Inc. (INTS), another Medical stock, has also outperformed the sector with a year-to-date return of 13.6% [4][6]

Core Insights - Zacks Premium offers various tools to help investors make informed decisions and enhance their confidence in stock market investments [1][2] Zacks Style Scores - The Zacks Style Scores are indicators designed to assist investors in selecting stocks with the highest potential to outperform the market within a 30-day timeframe [3] - Stocks are rated from A to F based on their value, growth, and momentum characteristics, with A indicating the highest potential for outperformance [3] Value Score - The Value Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [4] Growth Score - The Growth Score evaluates a company's financial health and future prospects by analyzing projected and historical earnings, sales, and cash flow [5] Momentum Score - The Momentum Score helps investors capitalize on price trends by assessing short-term price changes and earnings estimate revisions [6] VGM Score - The VGM Score combines the Value, Growth, and Momentum Scores, providing a comprehensive indicator for stock selection [7] Zacks Rank - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to guide investors in building successful portfolios [8] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [9] Stock Selection Strategy - To maximize returns, investors should target stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [11] - Stocks with lower ranks but high Style Scores may still be considered, provided they show potential for upside [11][12] Company Spotlight: Cencora - Cencora, based in Chesterbrook, PA, is a leading pharmaceutical services company focused on drug distribution and healthcare cost reduction [13] - Cencora holds a Zacks Rank of 2 (Buy) and a VGM Score of B, indicating strong growth potential [13] - The company is projected to achieve year-over-year earnings growth of 11.6% for the current fiscal year, with upward revisions in earnings estimates from analysts [14]

Industry Overview - The Medical Services sector is undergoing significant transformation driven by technological advancements, value-based care adoption, and a focus on patient-centric solutions and precision medicine [1] - The industry includes various service providers such as pharmacy benefit managers, contract research organizations, and healthcare workforce solution providers, moving from volume- to value-based care [4] Market Trends - The global healthcare analytics market was valued at $43.1 billion in 2023, with a projected CAGR of 21.1% from 2024 to 2030 [2] - The digital health market is expected to grow at a CAGR of 9.2% from 2024 to 2028, while the global big data in healthcare market is estimated to increase from $78 billion in 2024 to $540 billion by 2035, representing a CAGR of 19.20% [5] - The demand for skilled nursing professionals is rising, with a projected deficit of over 100,000 healthcare workers in the U.S. by 2028 [3][6] Staffing Challenges - The healthcare staffing shortage is exacerbated by the aging population and the impact of COVID-19, with WHO projecting a shortfall of 9.9 million healthcare workers globally by 2030 [6] - Labor costs have increased significantly, with hospitals experiencing a 15.6% rise in labor expenses per adjusted discharge compared to pre-pandemic levels [6] Employment Projections - Employment for nurse anesthetists, nurse midwives, and nurse practitioners is projected to grow 40% from 2023 to 2033, with about 31,900 openings expected each year [8] Industry Performance - The Zacks Medical Services industry ranks 71, placing it in the top 29% of 246 Zacks industries, indicating positive near-term prospects [9] - The industry has underperformed compared to its sector and the S&P 500, with a collective loss of 17.1% over the past year [11] Valuation Metrics - The industry is currently trading at a forward P/E of 15.5X, compared to the S&P 500's 21.18X and the sector's 23.07X [14] Stock Recommendations - Doximity (DOCS) is a digital platform for U.S. medical professionals, with an expected earnings growth rate of 7.7% for fiscal 2026 [19][20] - Pediatrix Medical (MD) provides specialized pediatric services, with projected earnings growth rates of 2.7% and 4.1% for 2025 and 2026, respectively [23][24] - Cencora (COR) focuses on drug distribution and related services, with an expected earnings growth rate of 11.6% for fiscal 2025 [27][28]

Core Insights - Zacks Premium offers tools for investors to enhance their stock market strategies and confidence, including daily updates, research reports, and stock screens [1] - The Zacks Style Scores are designed to complement the Zacks Rank, providing ratings based on value, growth, and momentum methodologies to help investors identify stocks likely to outperform the market [2] Zacks Style Scores Overview - Each stock is rated from A to F based on value, growth, and momentum, with A being the highest score indicating a better chance of outperforming [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] Value Score - The Value Score identifies attractive and discounted stocks using various financial ratios such as P/E, PEG, and Price/Sales, appealing to value investors [3] Growth Score - The Growth Score emphasizes a company's financial health and future outlook, analyzing projected and historical earnings, sales, and cash flow to find stocks with sustainable growth [4] Momentum Score - The Momentum Score helps investors capitalize on price trends by analyzing short-term price changes and earnings estimate revisions [5] VGM Score - The VGM Score combines the three Style Scores to identify stocks with the best value, growth potential, and momentum, serving as a strong indicator alongside the Zacks Rank [6] Zacks Rank and Style Scores Interaction - The Zacks Rank utilizes earnings estimate revisions to guide investors in building successful portfolios, with 1 (Strong Buy) stocks historically yielding an average annual return of +25.41% since 1988 [7][8] - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [9] Company Spotlight: Cencora - Cencora, based in Chesterbrook, PA, is a leading pharmaceutical services company focused on drug distribution and healthcare cost reduction [11] - Cencora holds a Zacks Rank of 2 (Buy) and a VGM Score of A, with a Value Style Score of A due to a forward P/E ratio of 17.67, making it attractive for value investors [11] - Recent analyst revisions have increased Cencora's earnings estimate for fiscal 2025 by $0.27 to $15.36 per share, with an average earnings surprise of 4.9% [12]

Core Viewpoint - The article highlights Cencora (COR) as a promising growth stock, supported by its favorable Growth Score and Zacks Rank, indicating strong potential for outperformance in the market [2][10]. Earnings Growth - Cencora has a historical EPS growth rate of 14.7%, with projected EPS growth of 11.6% for the current year, surpassing the industry average of 8.6% [5][4]. Cash Flow Growth - The company exhibits a year-over-year cash flow growth of 12.9%, significantly higher than the industry average of -9%. Its annualized cash flow growth rate over the past 3-5 years stands at 14.1%, compared to the industry average of 9.7% [6][7]. Earnings Estimate Revisions - The current-year earnings estimates for Cencora have been revised upward, with the Zacks Consensus Estimate increasing by 0.2% over the past month, indicating a positive trend in earnings estimate revisions [8]. Overall Positioning - Cencora holds a Growth Score of B and a Zacks Rank of 2, positioning it well for potential outperformance, making it an attractive option for growth investors [10].

Core Viewpoint - Cencora's recent earnings report shows a mixed performance with adjusted earnings per share beating estimates, while GAAP earnings per share declined significantly due to prior year credits related to litigation expenses [2][3]. Financial Performance - Adjusted earnings per share for Q1 fiscal 2025 was $3.73, exceeding the Zacks Consensus Estimate of $3.50 by 6.6% and improving 13.7% year over year [2]. - GAAP earnings per share was reported at $2.50, down 16.1% from the previous year [2]. - Total revenues reached $81.49 billion, reflecting a year-over-year increase of 12.8% and surpassing the Zacks Consensus Estimate by 4.3% [4]. Segment Analysis - **U.S. Healthcare Solutions**: Revenues were $74 billion, up 13.6% year over year, driven by market growth and increased sales of GLP-1 drugs and specialty products [5]. - **International Healthcare Solutions**: Revenues amounted to $7.5 billion, a 5.5% increase year over year, with operating income at $182.1 million, down 2.9% on a reported basis [7]. Margin Analysis - Adjusted gross profit was $2.5 billion, up 6.1% year over year, with an adjusted gross margin of 3.1%, down 20 basis points from the previous year [8]. - Adjusted operating income was $949.3 million, up 7.2% year over year, with an adjusted operating margin of 1.2%, contracting 7 basis points from the prior year [8]. Financial Update - Cash and cash equivalents at the end of Q1 were $3.22 billion, an increase from $3.13 billion in the previous quarter [9]. - Cumulative net cash used in operating activities was $2.72 billion, compared to $885.2 million in net cash provided a year ago [10]. Dividend Update - Cencora's board declared a quarterly dividend of 55 cents per share, payable on March 3, 2025, to shareholders of record on February 14, 2025 [11]. FY25 Guidance - The company updated its fiscal 2025 earnings and revenue outlook, projecting adjusted earnings per share in the range of $15.15-$15.45, indicating growth of 8-10% from the prior year [12]. - Revenue growth is now expected to be 8-10%, up from the previous guidance of 7-9% [13]. - Adjusted operating income is anticipated to improve by 11.5-13.5%, an increase from the earlier guidance of 5-6.5% [13]. Market Position - Cencora has a Zacks Rank 2 (Buy) and is expected to deliver above-average returns in the coming months despite a recent downward trend in estimates [17].

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying strong candidates can be challenging due to inherent risks and volatility [1] Group 1: Company Overview - Cencora (COR) is identified as a promising growth stock, supported by a favorable Growth Score and a top Zacks Rank [2] - The company has a historical EPS growth rate of 14.7%, with projected EPS growth of 11.1% this year, surpassing the industry average of 11% [4] Group 2: Financial Metrics - Cencora's year-over-year cash flow growth stands at 12.9%, significantly higher than the industry average of -10.5% [5] - The company's annualized cash flow growth rate over the past 3-5 years is 14.1%, compared to the industry average of 13.4% [6] Group 3: Earnings Estimates - There is a positive trend in earnings estimate revisions for Cencora, with the current-year earnings estimates increasing by 0.3% over the past month [7] - Cencora has achieved a Growth Score of B and a Zacks Rank of 2, indicating strong potential for outperformance [9]

iREIT+HOYA Capital is the premier income-focused investing service on Seeking Alpha. Our focus is on income-producing asset classes that offer the opportunity for sustainable portfolio income , diversification , and inflation hedging . Get started with a Free Two-Week Trial and take a look at our top ideas across our exclusive income-focused portfolios.There’s value to be had in buying boring businesses that deliver shareholder returns year in and out. Such companies may not be household names like NVIDIA C ...